105 results about "Cathepsin B" patented technology

A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the 10 method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a 13 receptor blocker; an imidazoline receptor antagonist; a centrally acting tx receptor antagonist; a peripherally acting ct receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

The invention relates to a micromolecular conjugate based on RGD polypeptide-chemotherapy drug and a self-assembly nanometer prodrug system thereof, and belongs to the technical field of biological medicine and nanometer medicine. The nanometer prodrug system has the main advantages that (1) the system is formed by RGD polypeptide and an anti-tumor drug through direct covalent connection via micromolecular connecting arms, and the drug loading capacity of the system is improved; (2) the conjugate is self-assembled into a nanometer prodrug using the drug as a hydrophobic inner core and the RGD polypeptide as a hydrophilic outer shell, the active targeting on tumor cells and tumor new vessels is realized through the ligand-receptor mutual action, and the endocytosis is promoted; (3) the stability of the nanometer prodrug system in the body circulation can be ensured through thioether bonds, reduction sensitive bonds and cathepsin B sensitive bonds, and the cytotoxic drug is released when the nanometer prodrug system reaches the tumor microenvironment; and (4) the micromolecular conjugate instead of a macromolecular material is used as a carrier, so that the nanometer prodrug system can favorably and better penetrate into the tumor tissues and cells to achieve better anti-tumor effects.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of alectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, cellular retinol-binding protein (CRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium/calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

The invention discloses a novel cathepsin B activation type targeted anti-tumor polypeptide m(KLA)-iRGD, the molecular weight is 2570, and the amino acid sequence is D(KLAKLAKKLAKLA)KGGCRGDKGPDC. The polypeptide is formed by KLA peptide and iRGD peptide through flexible connexon Gly-Gly. The sequence of the KLA peptide is KLAKLAKKLAKLAK, and amino acids of the KLAKLAKKLAKLA sequence at the N terminal of the polypeptide are all D-amino acids. The sequence of the iRGD peptide is CRGDKGPDC. The polypeptide has the advantage that the tumor targeted peptide iRGD and the apoptosis promoting peptide KLA are connected into the new polypeptide m(KLA)-iRGD for the first time. The polypeptide m(KLA)-iRGD can be specifically combined with alphaVbeta3 and NRP-1 receptors and enter tumor cells, mitochondrial apoptosis is initiated after the polypeptide is activated by intracellular cathepsin B (CTSB), tumor cells are selectively killed, and growth and migration of tumors are remarkably inhibited. Under the same concentration, a polypeptide m(KLA)-iRGD comparison peptide has higher tumor targeting and higher capacity of inhibiting tumor growth and migration. Meanwhile, the polypeptide m(KLA)-iRGD has no obvious toxicity on mouse weight and vital organs, and a solid foundation is laid for further clinical research and application.

The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.

The invention relates to a method for separating and purifying intestinal tract cathepsin B of a sea cucumber, which comprises the following steps: using sodium acetate buffer solution containing L-Cys to lixiviate a sea cucumber intestine homogenate breaking buffer solution at a temperature of 4 DEG C; adopting ammonia sulfate to perform fractional precipitation; using the sodium acetate buffer solution to dissolve the precipitate; and concentrating the dissolved precipitate after dialysis and demineralization to obtain crude enzyme of the cathepsin B. The crude enzyme of the cathepsin B is processed by 2 to 3 methods of ion exchange chromatography chromatogram, gel chromatogram and high-efficiency liquid chromatogram to achieve the aim of purification.

The invention relates to a low-molecular-weight L-polyglutamine-mitomycin C with the structural formula shown in the specification and the molecular weight of 1882Da-5892Da, wherein n is equal to 1500-6000. A synthesis method comprises the following steps: dissolving polyglutamic acid into water, stirring and then separating with sephadex chromatography to take polyglutamic acid with molecular weight of 1500-6000, performing freeze-drying and then adding dioxane, N-hydroxysuccinimide, a condensing agent and an acid-binding agent, evaporating out solvents and dissolving chloroform, washing with diluted hydrochloric acid and then evaporating the chloroform layer to dryness, adding a product to HBS buffer, adding mitomycin C under stirring, and then stirring reaction liquid and concentrating to dryness, and separating by using silicon gel column chromatography to obtain the low-molecular-weight L-polyglutamine-mitomycin C. The mitomycin C is modified by utilizing low-molecular-weight L-polyglutamine, and cannot penetrate cornea due to large molecular weight; the low-molecular-weight L-polyglutamine-mitomycin C can be accumulated in pterygium tissues through EPR effect; and the release of mitomycin C can be mediated by cathepsin B enzyme in the pterygium tissues so as to achieve the treatment effect.

The invention discloses a fluorescence probe and a synthetic method thereof and an application of the fluorescence probe in circulating tumor cell detection. The fluorescence probe comprises a fluorescence group, a cathepsin B substrate and folic acid molecules, the fluorescence group is connected with the cathepsin B substrate through a self-degradation bond, and then is connected with the folic acid molecules; the fluorescence group is excited by the excitation light under a dissociation state, and then is enable covalent connection with other molecules for quenching. The fluorescence probe is the switching-mode fluorescence probe having a spontaneous cascade amplification function, can be used for avoiding complex operation steps of antibody or nucleic acid detection during a circulating tumor cell detection process, is used for an automatic biochemical analyzer as a matching reagent, is in favor of promoting automation detection of tumor cells, and has the advantages of simple and convenient operation, short time consuming, and low apparatus requirement. The fluorescence probe can be used for positioning minimal tumor cells and tubercle in clinical operation, and has wide application prospect and large market value.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2-microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

The invention provides a tumor microenvironment stimulation degradable amphiphilic block HPMA (hydroxypropyl methacrylate) polymer delivery system which is a conjugate of HPMA polymer, cathepsin B substrate GFLG, and small-molecular drug gemcitabine; the nano delivery system formed by self-assembly of the amphiphilic block conjugate has enzyme responsive degrading capacity and drug release capacity, gemcitabine is delivered by being conjugated to the amphiphilic block HPMA polymer skeleton, the molecular weight of the system is relatively high, the system may effectively collect at a tumor part, has good biocompatibility and antitumor effect, and by introducing near-infrared fluorescent probe Cy5.5, self-tracing capacity is imparted to the system.

The invention discloses a disease resistance evaluation method of cultured shrimps and crabs, and belongs to the technical field of aquatic products. Infection with equivalent pathogens is performed according to muscle weight proportions of the cultured shrimps and crabs, nine indexes of the cultured shrimps and crabs are measured including pathogen clearance power, blood cell quantities, haemocyanin contents, blood plasma AKP vitality, ALF, crustin, lysozyme, cathepsin B and LGBP, a disease resistance exponent f of an infected object is obtained by use of principal component analysis, it is indicated that the bigger the f value is, the stronger the disease resistance is, and the smaller the f value is, the weaker disease resistance is. A set of exponents adapted to integrate evaluation of the disease resistance of the cultured shrimps and crabs is constructed for solving the problem of lack of similar technologies in the field, the evaluation result is more accurate, and restrictions and uncertainties of the mode of evaluating the disease resistance through a single immunization index are overcome.

The invention provides a biosensor for detecting cathepsin B as well as a detection method and application thereof, and belongs to the technical field of detection analysis. The biosensor at least comprises a polypeptide-DNA conjugate, a DNA template 1 and a DNA template 2. First primer DNA containing an amino acid residue is converted into new primer DNA containing no amino acid residue, the steric hinerance effect in a nucleic acid amplification process can be completely eliminated, and the amplification reaction efficiency can be improved. Meanwhile, proceeding of multiple chain replacementreactions and the circulating digestion function of ribonuclease H can further amplify a fluorescence signal, so that ultra-sensitive detection of the activity of cathepsin B can be realized, and thebiosensor has good practical application values.

The present invention relates to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

The invention discloses an enzyme-sensitive and redox-sensitive dual response type copolymer as well as a preparation method and application thereof and belongs to the fields of high polymer chemistryand pharmaceutical preparations. The preparation method in the invention comprises the following steps: binding polyacrylic acid and vitamin E succinate by utilizing valine-citrulline (Val-Cit, VC) fragments capable of being specifically hydrolyzed by cathepsin B and disulfide bonds capable of being reduced by glutathione, thereby obtaining the dual sensitive type copolymer polyacrylic acid-VC-SS-vitamin E succinate (PAA-VC-SS-VES). The copolymer is excellent in biocompatibility and high in sensitivity, can be self-assembled to form nano-micelles in water, can be coated with hydrophobic drugs, is mainly applied to treating tumor related diseases and has an effect of intelligently releasing the drugs.